<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856724</url>
  </required_header>
  <id_info>
    <org_study_id>145</org_study_id>
    <nct_id>NCT02856724</nct_id>
  </id_info>
  <brief_title>Early Amniotomy After Vaginal Prostaglandin E2 for Induction of Labor at Term: a Randomized Clinical Trial</brief_title>
  <acronym>PGE2</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness and safety of early amniotomy after vaginal
      prostaglandin E2 for induction of labor at term. Early amniotomy will be done in the early
      active phase of labor for early amniotomy group ( half of participants) when the cervix will
      dilated 3 cm using the amniotomy hook. Amniotomy will not be done for control group(other
      half of participants) until the membranes rupture spontaneously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During induction of labour, amniotomy (defined as artificial rupture of fetal membranes) is
      commonly used in combination with induction of labor. However, there is a lack of data on
      both effectiveness and ideal timing of this procedure. Yet for patients with an unfavorable
      cervix, a sharply ripening agent may be considered. As is well known to all,prostaglandin
      works efficiently in cervical ripening and labor induction. So dinoprostone surely performs
      quite well in promoting cervical ripening and labor induction since its main component is
      prostaglandin E2 (PGE2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>induction-to- delivery time</measure>
    <time_frame>delivery (the length of time between the beginning of induction and the end of labor)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mode of labor (vaginal or C-section)</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>successful induction</measure>
    <time_frame>vaginal delivery within 24 h from the beginning of induction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Early Amniotomy, Unfavorable Cervix</condition>
  <arm_group>
    <arm_group_label>Early amniotomy and PGE2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PGE2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg PGE2 vaginal ovul(Propess)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGE2</intervention_name>
    <description>10 mg PGE2 vaginal ovul(Propess)</description>
    <arm_group_label>Early amniotomy and PGE2</arm_group_label>
    <arm_group_label>PGE2</arm_group_label>
    <other_name>dinoprostone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. singleton pregnancy,

          2. gestational age ≥34 weeks,

          3. intact membranes,

          4. cephalic presentation,

          5. bishop score ≤5,

          6. had obstetrical indications for induction of labor,

          7. had less than three uterine contractions in every 10 minutes.

        Exclusion Criteria:

          1. Patients who have contraindications for vaginal delivery,

          2. previous uterine surgery,

          3. fetal malpresentation,

          4. multifetal pregnancy,

          5. more than three contractions in 10 minutes,

          6. contraindications to prostaglandins,

          7. a category II or III fetal heart rate pattern,

          8. anomalous fetus,

          9. fetal demise

         10. women with immediate delivery indications -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>evrim bostanci ergen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zeynep Kamil Maternity and Children's Training and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zeynep Kamil Woman and Child Diseases Education and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://nih.gov</url>
  </link>
  <reference>
    <citation>Ozkan S, Calişkan E, Doğer E, Yücesoy I, Ozeren S, Vural B. Comparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial. Arch Gynecol Obstet. 2009 Jul;280(1):19-24. doi: 10.1007/s00404-008-0843-9. Epub 2008 Nov 26.</citation>
    <PMID>19034471</PMID>
  </reference>
  <reference>
    <citation>Wei S, Wo BL, Qi HP, Xu H, Luo ZC, Roy C, Fraser WD. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev. 2013 Aug 7;(8):CD006794. doi: 10.1002/14651858.CD006794.pub4. Review.</citation>
    <PMID>23926074</PMID>
  </reference>
  <results_reference>
    <citation>Makarem MH, Zahran KM, Abdellah MS, Karen MA. Early amniotomy after vaginal misoprostol for induction of labor: a randomized clinical trial. Arch Gynecol Obstet. 2013 Aug;288(2):261-5. doi: 10.1007/s00404-013-2747-6. Epub 2013 Feb 21.</citation>
    <PMID>23430026</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Ahmet Eser</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

